Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ImClone, sanofi-aventis, Weizmann Institute of Science antibodies, cancer news

IMCL and SAN settled patent litigation related to Erbitux cetuximab with Yeda Research and Development Co. Ltd. (Rehovot, Israel), the licensing arm of the institute. The settlement acknowledges that Yeda is the

Read the full 327 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE